Genelux Investor Presentation Deck

Highlights of Genelux Execution GENELUX I Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICETM Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes O Validating Strategic Partnerships Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global rights) initiating canine efficacy studies with V-VET1 Focused Commercial Strategy US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings 32

View entire presentation